Sophia Genetics expands collaboration with AstraZeneca

Sophia Genetics (SOPH) announced an expansion of its collaboration with AstraZeneca (AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing solution that leverages SOPHiA GENETICS’s AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway. As part of the agreement, SOPHiA GENETICS will roll out a Privileged Access Program to selected clinical laboratories specializing in breast and prostate cancer research to validate sensitivity in a real-world setting, with broader commercial availability expected in 2026, alongside a multi-center real-world evidence study to further test its effectiveness. SOPHiA GENETICS’s global network will also help drive adoption of advanced PIK3CA/AKT1/PTEN testing in both tissue and liquid biopsy to expand patient access to precision therapies.